Yun Yang

Yun Yang

Auto-generated profile, based on publicly available information

Yun Yang

Yunnan Key Laboratory of Cross-Border Infectious Disease Control and Prevention and Novel Drug Development, Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ZFZiqi Feng
Ziqi Feng
ZWZelin Wang
Zelin Wang
YYYun Yang
Yun Yang
YDYuzhi Du
Yuzhi Du
SCSixin Cui
Sixin Cui
HSHongwu Sun
Hongwu Sun

18 September 2025 in Emerging Microbes & Infections
Verified
Journal Article
Open access
YYYuhuan Yan
Yuhuan Yan
JWJunbin Wang
Junbin Wang
HYHao Yang
Hao Yang
YYYun Yang
Yun Yang
LYLonghai Yuan
Longhai Yuan
XPXiaozhong Peng
Xiaozhong Peng
The multiple epidemics of Zika virus (ZIKV) posed a substantial threat to public health. Clinical evidence suggests that ZIKV could break through the blood-brain, blood-placenta, and blood-testis barriers, leading to severe outcomes such as congenital malformations in newborns and Guillain-Barré syndrome in adults. Currently, there are no specific treatments for ZIKV infection. To address the antibody-dependent enhancement (ADE) of dengue virus (DENV) infection induced by ZIKV vaccination, we designed two modified prM-E RNAs (ZA and ZB) with specific mutations either shielding or disrupting the conserved fusion-loop epitope in the E protein. Then, we chose the mRNA-LNP vaccine platform to evaluate the safety and efficacy. After prime-boost immunization, ZA vaccine could induce high levels of T cells secreting IFN-γ and exhibit limited neutralizing ability against Asian-lineage and African-lineage ZIKV. After ZIKV challenge, ZA vaccine could provide complete protection in immunocompromised AG129 mice at low levels of neutralizing antibodies, preventing viral dissemination to the brain, uterus, and testes. Importantly, the ZA vaccine also reduced the ADE effect of DENV infection. Although ZB vaccine exhibited good immunogenicity, it could not achieve complete viral clearance in AG29 mice. Our findings suggested that the ZA vaccine could prevent both lethal ZIKV infection and DENV ADE induced by infection or vaccination.